Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · IEX Real-Time Price · USD
10.43
0.00 (0.00%)
May 2, 2024, 4:00 PM EDT - Market closed
Amicus Therapeutics Revenue
In the year 2023, Amicus Therapeutics had annual revenue of $399.36M with 21.30% growth. Revenue in the quarter ending December 31, 2023 was $115.08M with 30.63% year-over-year growth.
Revenue (ttm)
$399.36M
Revenue Growth
+21.30%
P/S Ratio
7.74
Revenue / Employee
$772,449
Employees
517
Market Cap
3.09B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 399.36M | 70.12M | 21.30% |
Dec 31, 2022 | 329.23M | 23.72M | 7.76% |
Dec 31, 2021 | 305.51M | 44.63M | 17.11% |
Dec 31, 2020 | 260.89M | 78.65M | 43.16% |
Dec 31, 2019 | 182.24M | 90.99M | 99.72% |
Dec 31, 2018 | 91.25M | 54.32M | 147.08% |
Dec 31, 2017 | 36.93M | 31.97M | 644.86% |
Dec 31, 2016 | 4.96M | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 1.22M | 861.00K | 237.19% |
Dec 31, 2013 | 363.00K | -18.05M | -98.03% |
Dec 31, 2012 | 18.41M | -3.02M | -14.10% |
Dec 31, 2011 | 21.43M | 20.51M | 2,224.73% |
Dec 31, 2010 | 922.00K | -63.44M | -98.57% |
Dec 31, 2009 | 64.36M | 49.39M | 330.00% |
Dec 31, 2008 | 14.97M | 13.18M | 738.96% |
Dec 31, 2007 | 1.78M | - | - |
Dec 31, 2006 | 0 | - | - |
Dec 31, 2005 | 0 | - | - |
Dec 31, 2004 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Amedisys | 2.25B |
LivaNova | 1.15B |
Azenta | 641.02M |
Immunocore Holdings | 249.43M |
TransMedics Group | 241.62M |
Olink Holding AB (publ) | 169.60M |
IDEAYA Biosciences | 23.39M |
Janux Therapeutics | 8.08M |
FOLD News
- 1 day ago - Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024 - GlobeNewsWire
- 6 weeks ago - Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report - GlobeNewsWire
- 2 months ago - Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024 - GlobeNewsWire
- 2 months ago - Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates - GlobeNewsWire
- 2 months ago - Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024 - GlobeNewsWire
- 3 months ago - Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™ - GlobeNewsWire
- 3 months ago - Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024 - GlobeNewsWire
- 4 months ago - Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook - GlobeNewsWire